ArticleLung
Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer.
Article in Lung. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic impact of serum and tissue MMP-9 in non-small cell lung cancer: a systematic review and meta-analysis.Oncotarget · 2016Pooled it
- High circulating VEGF level predicts poor overall survival in lung cancer.Journal of cancer research and clinical oncology · 2013Pooled it
- Trial
- Assessment of serum vascular endothelial growth factor, nitric oxide and asymmetric dimethyl arginine levels in non-small cell lung cancer.Northern clinics of Istanbul · 2025Article
- Evaluation of prognostic value of vascular endothelial growth factor and endocan in non-small cell lung cancer.Turkish journal of medical sciences · 2025Article
- Endothelial progenitor cells as an angiogenic biomarker for the diagnosis and prognosis of lung cancer.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024Article
- Matrix Metallopeptidase-Gene Signature Predicts Stage I Lung Adenocarcinoma Survival Outcomes.International journal of molecular sciences · 2023Article
- Diagnostic and prognostic value of serum miR-145 and vascular endothelial growth factor in non-small cell lung cancer.Oncology letters · 2022Article
- Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer.Oncology letters · 2016Article
- The Different Effect of VEGF Polymorphisms on the Prognosis of Non-Small Cell Lung Cancer according to Tumor Histology.Journal of Korean medical science · 2016Article
- Sequential measurements of serum matrix metalloproteinase 9 to monitor chemotherapy responses in patients with advanced non-small-cell lung cancer.OncoTargets and therapy · 2016Article
- Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients.World journal of gastroenterology · 2015Article
- Expression levels of matrix metalloproteinase-9 in human gastric carcinoma.Oncology letters · 2015Article
- Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer.Oncology letters · 2014Article
- Detection of circulating vascular endothelial growth factor and matrix metalloproteinase-9 in non-small cell lung cancer using Luminex multiplex technology.Oncology letters · 2014Article
- [Changes in serum vascular endothelial growth factor and matrix metalloproteinase-9 after video-assisted thoracoscopic surgery and thoracotomic Lobectomy in the treatment of patients with non-small cell lung cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2014Article
- Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Review
- Tryptase serum levels in patients suffering from hepatocellular carcinoma undergoing intra-arterial chemoembolization: Possible predictive role of response to treatment.Molecular and clinical oncology · 2013Article
- Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer.Molecular pharmaceutics · 2012Article
- Updating advances on recombinant human endostatin combined with radiotherapy for non-small cell lung cancer with brain metastasis.Translational lung cancer research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9 are involved in angiogenesis of various cancers, clinical utility of preoperative serum concentration of these molecules in non-small cell lung cancer (NSCLC) has not yet been elucidated. In this study, we determined the concentration of VEGF, MMP-9 and various other tumor markers in serum prior to surgery and evaluated the results compared with intratumoral vasculature to isolate a valuable marker in determining the prediction of angiogenesis in NSCLC. Among these molecules and serum tumor markers, circulating serum VEGF was identified to markedly correlate with microvessel density (MVD) of the resected tumor specimens. Moreover, overall survival of patients with low VEGF levels (< or =326 ng/ml) was significantly greater than that of patients with high VEGF levels (>326 ng/ml), while patients with low MMP-9 levels (< or =189 ng/ml) and those with high MMP-9 levels (>189 ng/ml) revealed similar overall survival. Conclusively, preoperative concentration of serum VEGF may be the most valuable marker in the prediction of intratumoral angiogenesis and prognosis of patients with NSCLC.
Indexed as
Identifiers
15793665What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.